Provided are devices, systems and methods for determining whether a patient is immune to an infection or a disease caused by a coronavirus, such as severe acute respiratory coronavirus 2 (SARS-CoV-2). Devices and systems described herein are cost effective, scalable, and may be used at the point of need or point of care without a specialized training. The systems and devices described herein are useful for vaccine development, screening convalescent plasma therapies, and for identifying individuals who are eligible for reintegration following a period of quarantine.

Described herein are systems and methods for detecting and quantifying analytes. Also described herein are systems and methods for detecting and quantifying analytes stemmed from infections.

Provided are devices, systems and methods for determining whether a patient is immune to an infection by a disease-causing pathogen.

Provided are methods, devices, and systems for measuring analytes in biological samples. Also provided are methods, devices, and systems for detecting analytes in biological samples.

Provided are devices, systems and methods for determining whether a patient is immune to an infection or a disease caused by a coronavirus, such as severe acute respiratory coronavirus 2 (SARS-CoV-2). Devices and systems described herein are cost effective, scalable, and may be used at the point of need or point of care without a specialized training. The systems and devices described herein are useful for vaccine development, screening convalescent plasma therapies, and for identifying individuals who are eligible for reintegration following a period of quarantine.

A rapid diagnostic test strip, system, and methodology are disclosed. The test strips utilize a sample pad on a proximal portion of a substrate. When a sample (potentially containing various analytes) is provided to the sample pad, it is transported to a conjugate release pad located distally from the sample pad. The conjugate release pad includes two or more targeted materials, where each targeted material includes an upconverting rare-earth particle capable of conjugating to an analyte. The conjugated analytes are then transported distally along the test strip, where they may bind to one or more test lines. An absorbent pad is located distally from the test lines. The one or more test lines can the be briefly illuminated with one or more specific wavelengths of light that the rare-earth particles absorb, and the rare-earth particles then emit a response that can be detected and measured.

Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

Two or more upconverting particles are attached to each unit of one or more units of a chemical component in a sample, to form, for each unit of the chemical component, a multi-particle complex including the unit of the chemical component and two or more corresponding upconverting particles. The sample is illuminated by input light having a first wavelength. Light is received at an imaging sensor, the received light including output light generated by at least a portion of the upconverting particles attached to the units of the chemical component, the output light having a second wavelength that is shorter than the first wavelength. One or more images of the sample are captured from the received light. Based on the captured one or more images, a presence or a level of the chemical component in the sample is determined.

The present disclosure an ELISA-based assay that uses a glycosylated s1F polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) spike protein, the N-terminal domain of which has affinity for the tyrosine-protein kinase receptor UFO (AXL). The S1F polypeptide can be generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed S1F polypeptide at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1F for AXL, provides a significant increase in the sensitivity of the assay compared to other known assays. Further the AXL polypeptide can be glycosylated, which further increases the affinity for S1F and AXL to each other.

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.